72131-30-7

Upstream product

• 60-19-5 tyramine hydrochloride 
• 198756-78-4 C₂₀H₂₃NO₅ 
• 72131-35-2 4-[2-(4-methoxybenzenesulphonylamino)-ethyl]-phenoxyacetic acid 

Downstream Products

• 72131-67-0 [4-(2-{2-[4-(2-Benzenesulfonylamino-ethyl)-phenoxy]-acetylamino}-ethyl)-phenoxy]-acetic acid ethyl ester 
• 1350846-83-1 ethyl 2-[4-(2-heptanoylaminoethyl)phenoxy]ethanoate 
• 1350961-29-3 2-(4-{2-[N-(heptyl)-N-(benzoxazol-2-yl)amino]ethyl}phenoxy)ethanoic acid 
• 1350846-87-5 ethyl 2-(4-{2-[N-(heptyl)-N-(benzoxazol-2-yl)amino]ethyl}phenoxy)ethanoate 
• 1350846-74-0 sodium 2-(4-{2-[N-(heptyl)-N-(benzoxazol-2-yl)amino]ethyl}phenoxy)ethanoate 
• 1350846-95-5 ethyl 2-[4-(2-heptylaminoethyl)phenoxy]ethanoate 
• 72131-68-1 [4-(2-{2-[4-(2-Benzenesulfonylamino-ethyl)-phenoxy]-acetylamino}-ethyl)-phenoxy]-acetic acid 
• 1177146-17-6 C₂₀H₂₀ClN₃O₃ 

Relevant academic research and scientific papers

Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity

A series of ureidofibrate-like derivatives was prepared and assayed for their PPAR functional activity. A calorimetric approach was used to characterize PPARγ-ligand interactions, and docking experiments and X-ray studies were performed to explain the obs

Compound with platelet aggregation inhibitor activity

A compound represented by the general formula (I) and a pharmaceutically acceptable salt and solvate thereof having an effect for inhibiting the agglutination of platelets is disclosed: STR1 wherein R1 represents a group --W--(CH2)i --COOR3, R2 represents a hydrogen atom or a group --W--(CH2)i --COOR3 or --OR4, X represents --CH= or --N=, Y represents (i) a group --(CO)k --N(R5)--Z--, wherein Z represents a bond or a group --(CH2)m --CO-- or a group --(CH2)m --CHR6 --, (ii) a group --(CH2)m --N(R5)--(CO)k --, or (iii) a group --(CO)k -Het, wherein Het represents a five- or six-membered heterocyclic ring comprising a nitrogen atom, A represents (i) the following groups (III) or (IV) STR2 B represents a bond, C1-6 alkylene or C2-6 alkenylen.

Phenoxyalkylcarboxylic acid compounds and thrombocyte-aggregation inhibition

Phenoxyalkylcarboxylic acid compounds of the formula STR1 wherein R is hydrogen or lower alkyl R1 is alkyl or aryl, aralkyl or aralkenyl radical, the aryl moiety of which can be substituted one or more times by halogen, hydroxyl, trifluoromethyl or lower alkyl, alkoxy or acyl R2 and R3 are individually selected from hydrogen or lower alkyl, and n is 0, 1, 2 or 3 and the physiologically acceptable salts, esters and amides thereof; are outstandingly effective in inhibiting thrombocyte aggregation.